CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation

Cyclin-dependent kinase 9 (CDK9), a key regulator of RNA-polymerase II, is a candidate drug target for cancers driven by transcriptional deregulation. Here we report a multi-omics-profiling of prostate cancer cell responses to CDK9 inhibition to identify synthetic lethal interactions. These interact...

Descripción completa

Detalles Bibliográficos
Autores principales: Itkonen, Harri M., Poulose, Ninu, Walker, Suzanne, Mills, Ian G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Short communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541904/
https://www.ncbi.nlm.nih.gov/pubmed/31151054
http://dx.doi.org/10.1016/j.neo.2019.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541904/
https://www.ncbi.nlm.nih.gov/pubmed/31151054
http://dx.doi.org/10.1016/j.neo.2019.05.001

Ejemplares similares